138 related articles for article (PubMed ID: 28791697)
41. Effect of transporter and DNA repair gene polymorphisms to lung cancer chemotherapy toxicity.
Chen J; Wu L; Wang Y; Yin J; Li X; Wang Z; Li H; Zou T; Qian C; Li C; Zhang W; Zhou H; Liu Z
Tumour Biol; 2016 Feb; 37(2):2275-84. PubMed ID: 26358256
[TBL] [Abstract][Full Text] [Related]
42. Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy.
Li Y; Sun Z; Cunningham JM; Aubry MC; Wampfler JA; Croghan GA; Johnson C; Wu D; Aakre JA; Molina J; Wang L; Pankratz VS; Yang P
Clin Cancer Res; 2011 Jun; 17(11):3830-40. PubMed ID: 21636554
[TBL] [Abstract][Full Text] [Related]
43. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients.
Chen S; Huo X; Lin Y; Ban H; Lin Y; Li W; Zhang B; Au WW; Xu X
Int J Hyg Environ Health; 2010 Mar; 213(2):140-5. PubMed ID: 20189873
[TBL] [Abstract][Full Text] [Related]
44. Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer--a pilot study.
Krawczyk P; Wojas-Krawczyk K; Mlak R; Kucharczyk T; Biernacka B; Milanowski J
Folia Histochem Cytobiol; 2012 Apr; 50(1):80-6. PubMed ID: 22532140
[TBL] [Abstract][Full Text] [Related]
45. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
[TBL] [Abstract][Full Text] [Related]
46. Association between CASP8 and CASP10 polymorphisms and toxicity outcomes with platinum-based chemotherapy in Chinese patients with non-small cell lung cancer.
Qian J; Qu HQ; Yang L; Yin M; Wang Q; Gu S; Wu Q; Zhao X; Wu W; Wu J; Tan X; Chen W; Wang H; Wang J; Fan W; Chen H; Han B; Lu D; Wei Q; Jin L
Oncologist; 2012; 17(12):1551-61. PubMed ID: 22843554
[TBL] [Abstract][Full Text] [Related]
47. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
Zhou C; Ren S; Zhou S; Zhang L; Su C; Zhang Z; Deng Q; Zhang J
Jpn J Clin Oncol; 2010 Oct; 40(10):954-60. PubMed ID: 20462983
[TBL] [Abstract][Full Text] [Related]
48. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
Zhou W; Gurubhagavatula S; Liu G; Park S; Neuberg DS; Wain JC; Lynch TJ; Su L; Christiani DC
Clin Cancer Res; 2004 Aug; 10(15):4939-43. PubMed ID: 15297394
[TBL] [Abstract][Full Text] [Related]
49. Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer.
Booton R; Ward T; Heighway J; Taylor P; Power F; Ashcroft L; Morris J; Thatcher N
Cancer; 2006 Jun; 106(11):2421-7. PubMed ID: 16649224
[TBL] [Abstract][Full Text] [Related]
50. Association between Genetic Variants and Peripheral Neuropathy in Patients with NSCLC Treated with First-Line Platinum-Based Therapy.
de Jong C; Herder GJM; van Haarlem SWA; van der Meer FS; van Lindert ASR; Ten Heuvel A; Brouwer J; Egberts TCG; Deneer VHM
Genes (Basel); 2023 Jan; 14(1):. PubMed ID: 36672910
[TBL] [Abstract][Full Text] [Related]
51. Prediction models for platinum-based chemotherapy response and toxicity in advanced NSCLC patients.
Yin JY; Li X; Li XP; Xiao L; Zheng W; Chen J; Mao CX; Fang C; Cui JJ; Guo CX; Zhang W; Gao Y; Zhang CF; Chen ZH; Zhou H; Zhou HH; Liu ZQ
Cancer Lett; 2016 Jul; 377(1):65-73. PubMed ID: 27126360
[TBL] [Abstract][Full Text] [Related]
52. Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer.
Lambrechts S; Lambrechts D; Despierre E; Van Nieuwenhuysen E; Smeets D; Debruyne PR; Renard V; Vroman P; Luyten D; Neven P; Amant F; Leunen K; Vergote I;
BMC Pharmacol Toxicol; 2015 Feb; 16():2. PubMed ID: 25881102
[TBL] [Abstract][Full Text] [Related]
53. Gene-gene and gene-environment interactions influence platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients.
Cui JJ; Wang LY; Zhu T; Gong WJ; Zhou HH; Liu ZQ; Yin JY
Sci Rep; 2017 Jul; 7(1):5082. PubMed ID: 28698656
[TBL] [Abstract][Full Text] [Related]
54. Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.
Liu L; Yuan P; Wu C; Zhang X; Wang F; Guo H; Zhong R; Xu Y; Wu J; Yu D; Wu T; Zhang X; Nie S; Miao X; Lin D
Lung Cancer; 2011 Jul; 73(1):110-5. PubMed ID: 21129812
[TBL] [Abstract][Full Text] [Related]
55. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
Glorieux P; Ortmanns P; Marien S; Degives R; Degraeve D; Potvin M; Grauwels D; Schallier D
Anticancer Res; 2001; 21(2B):1487-94. PubMed ID: 11396237
[TBL] [Abstract][Full Text] [Related]
56. The study of the relation of DNA repair pathway genes SNPs and the sensitivity to radiotherapy and chemotherapy of NSCLC.
Wang C; Nie H; Li Y; Liu G; Wang X; Xing S; Zhang L; Chen X; Chen Y; Li Y
Sci Rep; 2016 Jun; 6():26526. PubMed ID: 27246533
[TBL] [Abstract][Full Text] [Related]
57. Correlation of MSH3 polymorphisms with response and survival in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.
Xu XL; Yao YL; Xu WZ; Feng JG; Mao WM
Genet Mol Res; 2015 Apr; 14(2):3525-33. PubMed ID: 25966119
[TBL] [Abstract][Full Text] [Related]
58. Pharmacogenomics of platinum-based chemotherapy in non-small cell lung cancer: focusing on DNA repair systems.
Xiong Y; Huang BY; Yin JY
Med Oncol; 2017 Apr; 34(4):48. PubMed ID: 28215024
[TBL] [Abstract][Full Text] [Related]
59. Association of CASP3 polymorphism with hematologic toxicity in patients with advanced non-small-cell lung carcinoma treated with platinum-based chemotherapy.
Gu S; Wu Q; Zhao X; Wu W; Gao Z; Tan X; Qian J; Chen H; Xie Y; Jin L; Han B; Lu D
Cancer Sci; 2012 Aug; 103(8):1451-9. PubMed ID: 22568453
[TBL] [Abstract][Full Text] [Related]
60. Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung cancer patients.
Johnson C; Pankratz VS; Velazquez AI; Aakre JA; Loprinzi CL; Staff NP; Windebank AJ; Yang P
J Neurol Sci; 2015 Feb; 349(1-2):124-8. PubMed ID: 25586538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
